Thursday August 22, 2019

Researchers in Uganda Launch Ebola Vaccine Trial for Two Years

The new vaccine is manufactured by U.S.-based Janssen and Janssen company

0
//
ebola vaccine
FILE - A Ugandan health worker prepares to administer the Ebola vaccine to a man in Kirembo village, near the border with the Democratic Republic of Congo in Kasese district, Uganda, June 16, 2019. VOA

Eight hundred health workers involved in the fight against the Ebola virus are receiving doses of a two-part vaccine. Researchers who launched a trial this week for a new Ebola vaccine say the new vaccine trial will take two years to complete.

Dr. Juliet Mwanga, director of the Mbarara Research Center, said the vaccine combines antigen — a substance that induces an immune response in the body — from the Ebola virus, a common adenovirus, and the vaccinia Ankara vaccine. The new vaccine is manufactured by U.S.-based Janssen and Janssen company.

“This J and J vaccine aims at prevention — primary prevention before you have contact at all,” said Mwanga. “And the other difference, as I said, it has two parts. So, you’re given the first dose, and 56 days later, you get another dose, which boosts your immunity. So, hopefully it works for a longer time.”

ebola
Deo Bakulu has been washing his hands every chance he gets since Ebola reached eastern Democratic Republic of Congo’s main city of Goma. VOA

Currently, Uganda is using an Ebola vaccine by the Merck pharmaceutical company, but Mwanga said they need to try out new vaccines, too. Uganda’s move is motivated by its proximity to the Democratic Republic of Congo, where more than 1,800 people have died from an Ebola outbreak that began a year ago.

ALSO READ: Medicare Uses Breakthrough Gene Therapy to Cover Some Blood Cancers

Dr. Kimton Opio, the coordinator of the trial, said the vaccine is being tested on 800 health care workers and front-line support workers who meet a few basic requirements. “Someone has to be 18 years and over,” he said. ” Then, of course, they have to be able to sign the  [consent] form. Then they must not have been vaccinated with Ebola before, or they must have not suffered from Ebola before.”

The researchers are hopeful the vaccine, if effective, will help Uganda and neighboring countries that have endured Ebola outbreaks. Uganda has seen no new cases of Ebola in recent weeks. But, health officials have been on high alert since June, when two adults and a five-year-old boy who had crossed into Uganda from the DRC died of the virus. (VOA)

Next Story

Uganda Begins Largest-Ever Ebola Vaccine Trial to Prevent Disease from Speading

An epidemic across the border in neighboring Democratic Republic of Congo has killed over 1,800 people

0
ebola
FILE - Ugandan health workers speak to civilians before carrying out the first vaccination exercise against the Ebola virus in Kirembo village, near the border with the Democratic Republic of Congo in Kasese district, Uganda, June 16, 2019. VOA

Uganda has started its largest Ebola vaccine trial to date, health authorities announced Monday, in an apparent effort to prevent the disease from spreading. An epidemic across the border in neighboring Democratic Republic of Congo has killed over 1,800 people, making this outbreak the second-deadliest to date, with fatality rates nearing 70%.

The experimental Johnson & Johnson vaccine will be administered to health care professionals, as well as ambulance drivers, burial teams and cleaners. The trial is expected to last two years and cover 800 people in the Mbarara district in southwest Uganda.

Vaccinations have already begun, according to Uganda’s Medical Research Council. There are no licensed treatments for Ebola, but one vaccine, manufactured by Merck, was used effectively at the end of the 2013-2016 outbreak in the DRC and has been used during the current epidemic. Over 180,000 people have received this vaccine.

ebola
As the Ebola epidemic in the eastern Democratic Republic of Congo enters its second year, experts from the World Health Organization (WHO) are voicing concern. Pixabay

But the supply is sporadic, and vaccine administrators are typically 1,000 doses short of what they need, according to Doctors Without Borders as reported by Bloomberg News. Health professionals have called for the use of both the Johnson and Merck vaccines to maximize the number of people protected from Ebola.

ALSO READ: Eco-Friendly and Sustainable Furniture: How FurnitureRoots is Contributing to The Ecosystem with Environment-Friendly Furniture?

Some people, including the DRC’s former health minister, opposed the move, arguing that another vaccine with a different administration schedule would stoke vaccine distrust in vulnerable areas. While the Merck vaccine is administered through one shot and takes 10 days to be effective, the Johnson & Johnson vaccine requires two shots, two months apart.

Aside from sparking anti-vaccine fear, the Johnson & Johnson drug could be difficult to administer in practice, as violence in northeastern DRC hampers disease-control efforts. Neighboring countries have been on high alert since three people died of Ebola in the DRC city of Goma, located on the border with Rwanda and just a few hours from Uganda. (VOA)